Abstract
With the advancement of medical and investigative science, it is somewhat surprising that although it is possible to stabilise medical patients with hypertension and the associated kidney dysfunction, obesity, diabetes and even cancer, there is still no clear method of significantly reducing these chronic disease pathologies, and thus, extending life expectancy. There is one hormone common to these pathologies, the antagonism of which goes some way to clinical improvements, and this is angiotensin, which is released during hypovolaemia. Angiotensin antagonists are used to treat many of these pathologies, and it has been shown in the obesity literature that angiotensin antagonists decrease weight, but also increase the drinking of water. Increased cellular hydration, and hence, improved mitochondrial metabolism could be one of the mechanisms for the reduction in weight seen in these studies, as well as for reducing the other pathologies, all showing metabolic dysfunction. It appears that the application of straightforward physiological regulation might be an appropriate medical approach to the prevention of hypertension, kidney disease, obesity, diabetes and cancer, and thus, to an increased life expectancy.
Similar content being viewed by others
References
Ayus JC, Arieff AI (1996) Abnormalities of water metabolism in the elderly. Semin Nephrol 16:277–288
Baiardi G, Bregonzio C, Jezova M, Armando I, Saavedra JM (2004) Angiotensin II AT1 receptor blockade prolongs the lifespan of spontaneously hypertensive rats and reduces stress-induced release of catecholamines, glucocorticoids, and vasopressin. Ann NY Acad Sci 1018:131–136
Barnett A (2006) Prevention of loss of renal function over time in patients with diabetic nephropathy. Am J Med 119:S40–S47
Basso N, Paglia N, Cini R, Inserra F, Terragno NA (2005) Effect of omapatrilat on the aging process of the normal rat. Cell Mol Biol (Noisy-le-grand) 51:557–564
Basso N, Paglia N, Stella I, de Cavanagh EM, Ferder L, del Rosario Lores Arnaiz M, Inserra F (2005) Protective effect of the inhibition of the renin-angiotensin system on aging. Regul Pept 128:247–252
Basso N, Cini R, Pietrelli A, Ferder L, Terragno NA, Inserra F (2007) Protective effect of long-term angiotensin II inhibition. Am J Physiol Heart Circ Physiol 293:H1351–H1358
Bellisle F, Thornton SN, Hébel P, Denizeau M, Tahiri M (2010) A study of fluid intake from beverages in a sample of healthy French children, adolescents and adults. Eur J Clin Nutr 64:350–355
Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G (2009) Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 119:524–530
Besdine RW, Wetle TF (2010) Improving health for elderly people: an international health promotion and disease prevention agenda. Aging Clin Exp Res 22:219–230
Brown MJ (2007) Renin: friend or foe? Heart 93:1026–1033
Cadnapaphornchai MA, Rogachev B, Summer SN, Chen YC, Gera L, Stewart JM, Schrier RW (2004) Evidence for bradykinin as a stimulator of thirst. Am J Physiol Renal Physiol 286:F875–F880
Carey RM, McGrath HE, Pentz ES, Gomez RA, Barrett PQ (1997) Biomechanical coupling in renin-releasing cells. J Clin Invest 100:1566–1574
Carides GW, Shahinfar S, Dasbach EJ, Keane WF, Gerth WC, Alexander CM, Herman WH, Brenner BM, Investigators RENAAL (2006) The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. Pharmacoeconomics 24:549–558
Carter P, Gray LJ, Troughton J, Khunti K, Davies MJ (2010) Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis. BMJ 341:c4229
Cassis P, Conti S, Remuzzi G, Benigni A (2010) Angiotensin receptors as determinants of life span. Pflugers Arch 459:325–332
Chai W, Wang W, Liu J, Barrett EJ, Carey RM, Cao W, Liu Z (2010) Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use. Hypertension 55:523–530
Chobanian AV (2009) Shattuck lecture. The hypertension paradox–more uncontrolled disease despite improved therapy. N Engl J Med 361:878–887
Chumlea WC, Guo SS, Zeller CM, Reo NV, Siervogel RM (1999) Total body water data for white adults 18 to 64 years of age: The Fels Longitudinal Study. Kidney Int 56:244–252
Crowley RK, Sherlock M, Agha A, Smith D, Thompson CJ (2007) Clinical insights into adipsic diabetes insipidus: a large case series. Clin Endocrinol (Oxf) 66:475–482
Dai Q, Borenstein AR, Wu Y, Jackson JC, Larson EB (2006) Fruit and vegetable juices and Alzheimer's disease: the Kame Project. Am J Med 119:751–759
Dauchet L, Amouyel P, Dallongeville J, Medscape (2009) Fruits, vegetables and coronary heart disease. Nat Rev Cardiol 6:599–608
de Cavanagh EM, Piotrkowski B, Basso N, Stella I, Inserra F, Ferder L, Fraga CG (2003) Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB J 17:1096–1098
de Cavanagh EM, Piotrkowski B, Fraga CG (2004) Concerted action of the renin-angiotensin system, mitochondria, and antioxidant defenses in aging. Mol Aspects Med 25:27–36
de Cavanagh EM, Toblli JE, Ferder L, Piotrkowski B, Stella I, Fraga CG, Inserra F (2005) Angiotensin II blockade improves mitochondrial function in spontaneously hypertensive rats. Cell Mol Biol (Noisy-le-grand) 51:573–578
de Cavanagh EM, Inserra F, Ferder M, Ferder L (2007) From mitochondria to disease: role of the renin-angiotensin system. Am J Nephrol 27:545–553
de Cavanagh EM, Ferder L, Toblli JE, Piotrkowski B, Stella I, Fraga CG, Inserra F (2008) Renal mitochondrial impairment is attenuated by AT1 blockade in experimental Type I diabetes. Am J Physiol Heart Circ Physiol 294:H456–H465
de Cavanagh EM, Flores I, Ferder M, Inserra F, Ferder L (2008) Renin-angiotensin system inhibitors protect against age-related changes in rat liver mitochondrial DNA content and gene expression. Exp Gerontol 43:919–928
de Cavanagh EM, Ferder M, Inserra F, Ferder L (2009) Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am J Physiol Heart Circ Physiol 296:H550–H558
Elamin A, Hussein O, Tuvemo T (2006) Growth, puberty, and final height in children with Type 1 diabetes. J Diabetes Complications 20:252–256
Ferder LF, Inserra F, Basso N (2002) Advances in our understanding of aging: role of the renin-angiotensin system. Curr Opin Pharmacol 2:189–194
Ferder LF, Inserra F, Basso N (2003) Effects of renin-angiotensin system blockade in the aging kidney. Exp Gerontol 38:237–244
Fetissov SO, Thornton SN (2009) Hypovolemia-induced obesity and diabetes. Metabolism 58:1678
Fitzsimons JT (1998) Angiotensin, thirst, and sodium appetite. Physiol Rev 78:583–686
Formenti F, Constantin-Teodosiu D, Emmanuel Y, Cheeseman J, Dorrington KL, Edwards LM, Humphreys SM, Lappin TR, McMullin MF, McNamara CJ, Mills W, Murphy JA, O'Connor DF, Percy MJ, Ratcliffe PJ, Smith TG, Treacy M, Frayn KN, Greenhaff PL, Karpe F, Clarke K, Robbins PA (2010) Regulation of human metabolism by hypoxia-inducible factor. Proc Natl Acad Sci USA 107:12722–12727
Francischetti EA, Celoria BM, Francischetti A, Genelhu VA (2008) Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan. Expert Rev Cardiovasc Ther 6:289–303
Franklin RM, Kanaley JA (2009) Intramyocellular lipids: effect of age, obesity, and exercise. Phys Sportsmed 37:20–26
Gard PR (2004) Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Ther Targets 8:7–14
Gaster M (2009) Reduced lipid oxidation in myotubes established from obese and type 2 diabetic subjects. Biochem Biophys Res Commun 382:766–770
Gilliam-Davis S, Payne VS, Kasper SO, Tommasi EN, Robbins ME, Diz DI (2007) Long-term AT1 receptor blockade improves metabolic function and provides renoprotection in Fischer-344 rats. Am J Physiol Heart Circ Physiol 293:H1327–H1333
Gnudi L, Goldsmith D (2010) Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes. F1000 Med Rep 2:18
Gradman AH, Kad R (2008) Renin inhibition in hypertension. J Am Coll Cardiol 51:519–528
Häussinger D (1996) The role of cellular hydration in the regulation of cell function. Biochem J 313:697–710
Haveman-Nies A, de Groot LC, Van Staveren WA (1997) Fluid intake of elderly Europeans. J Nutr Health Aging 1:151–155
Hedner T, Narkiewicz K, Kjeldsen SE (2007) The evolution of ACE inhibition–a turning point in cardiovascular medicine. Blood Press Suppl 2:5–6
Henriksen EJ (2007) Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 293:R974–R980
Herbert KE, Mistry Y, Hastings R, Poolman T, Niklason L, Williams B (2008) Angiotensin II-mediated oxidative DNA damage accelerates cellular senescence in cultured human vascular smooth muscle cells via telomere-dependent and independent pathways. Circ Res 102:201–208
Hirabara SM, Curi R, Maechler P (2010) Saturated fatty acid-induced insulin resistance is associated with mitochondrial dysfunction in skeletal muscle cells. J Cell Physiol 222:187–194
Idbaih A, Burlet A, Adle-Biassette H, Boisgard R, Coulon C, Paris S, Marie Y, Donadieu J, Hoang-Xuan K, Ribeiro MJ (2007) Altered cerebral glucose metabolism in an animal model of diabetes insipidus: a micro-PET study. Brain Res 1158:164–168
Inserra F, Basso N, Ferder M, Userpater M, Stella I, Paglia N, Inserra P, Tenembaum D, Ferder L (2009) Changes seen in the aging kidney and the effect of blocking the renin-angiotensin system. Ther Adv Cardiovasc Dis 3:341–346
Janiak P, Bidouard JP, Cadrouvele C, Poirier B, Gouraud L, Grataloup Y, Pierre F, Bruneval P, O'Connor SE, Herbert JM (2006) Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats. Eur J Pharmacol 534:271–279
Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D, Egan GF, McKinley MJ, Rodger PD, Sinclair AJ, Wark JD, Weisinger HS, Jois M, Weisinger RS (2008) Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci USA 105:6531–6536
Jordan J (2002) Acute effect of water on blood pressure. What do we know? Clin Auton Res 12:250–255
Kehoe PG, Miners S, Love S (2009) Angiotensins in Alzheimer's disease - friend or foe? Trends Neurosci 32:619–628
Keller U, Szinnai G, Bilz S, Berneis K (2003) Effects of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. Eur J Clin Nutr 57:S69–S74
Kenney WL, Chiu P (2001) Influence of age on thirst and fluid intake. Med Sci Sports Exerc 33:1524–1532
Kositzke JA (1990) A question of balance-dehydration in the elderly. J Gerontol Nurs 16:4–11
Lang F (2007) Mechanisms and significance of cell volume regulation. J Am Coll Nutr 26:613S–623S
Lang F, Ritter M, Völkl H, Häussinger D (1993) The biological significance of cell volume. Ren Physiol Biochem 16:48–65
Lanza IR, Nair KS (2010) Mitochondrial function as a determinant of life span. Pflugers Arch 459:277–289
Laragh J (2001) Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 14:84–89
Laragh J (2001) Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 14:837–854
Laragh J (2001) Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 14:296–304
Lavizzo-Mourey RJ (1987) Dehydration in the elderly: a short review. J Natl Med Assoc 79:1033–1038
Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 340:b5465
Linz W, Jessen T, Becker RH, Schölkens BA, Wiemer G (1997) Long-term ACE inhibition doubles lifespan of hypertensive rats. Circulation 96:3164–3172
Linz W, Becker RH, Schölkens BA, Wiemer G, Keil M, Langer KH (1998) Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats. Kidney Int 54:2037–2044
Linz W, Wohlfart P, Schoelkens BA, Becker RH, Malinski T, Wiemer G (1999) Late treatment with ramipril increases survival in old spontaneously hypertensive rats. Hypertension 34:291–295
Linz W, Heitsch H, Schölkens BA, Wiemer G (2000) Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats. Hypertension 35:908–913
Ma TK, Kam KK, Yan BP, Lam YY (2010) Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 160:1273–1292
Majzoub JA, Srivatsa A (2006) Diabetes insipidus: clinical and basic aspects. Pediatr Endocrinol Rev 4:60–65
Mathai ML, Naik S, Sinclair AJ, Weisinger HS, Weisinger RS (2008) Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats. Int J Obes (Lond) 32:1576–1584
Mattson MP, Maudsley S (2009) Live longer sans the AT1A receptor. Cell Metab 9:403–405
May M, Jordan J (2010) The Osmopressor-response to water drinking. Am J Physiol Regul Integr Comp Physiol Nov 3. (in press)
Miller M (1997) Fluid and electrolyte homeostasis in the elderly: physiological changes of ageing and clinical consequences. Baillières Clin Endocrinol Metab 11:367–387
Mizrahi A, Knekt P, Montonen J, Laaksonen MA, Heliövaara M, Järvinen R (2009) Plant foods and the risk of cerebrovascular diseases: a potential protection of fruit consumption. Br J Nutr 102:1075–1083
Mogi M, Horiuchi M (2009) Effects of angiotensin II receptor blockers on dementia. Hypertens Res 32:738–740
Molaschi M, Ponzetto M, Massaia M, Villa L, Scarafiotti C, Ferrario E (1997) Hypernatremic dehydration in the elderly on admission to hospital. J Nutr Health Aging 1:156–160
Molteni A, Heffelfinger S, Moulder JE, Uhal B, Castellani WJ (2006) Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy. Anticancer Agents Med Chem 6:451–460
Morino K, Petersen KF, Shulman GI (2006) Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55:S9–S15
Moscarelli L, Zanazzi M, Mancini G, Rossi E, Caroti L, Rosso G, Bertoni E, Salvadori M (2010) Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients. Clin Nephrol 73:439–445
Muñoz MC, Argentino DP, Dominici FP, Turyn D, Toblli JE (2006) Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats. J Hypertens 24:1607–1617
Nagura J, Hui C, Yamamoto M, Yasuda S, Abe M, Hachisu M, Konno F (1995) Effect of chronic treatment with ME3221 on blood pressure and mortality in aged stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 22:S363–S365
Nagura J, Yamamoto M, Hui C, Yasuda S, Hachisu M, Konno F (1996) Protective effects of ME3221 on hypertensive complications and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 23:229–235
Nangaku M, Fujita T (2008) Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens Res 31:175–184
Nayak V, Patil PA (2008) Antidepressant activity of fosinopril, ramipril and losartan, but not of lisinopril in depressive paradigms of albino rats and mice. Indian J Exp Biol 46:180–184
Niklason A, Hedner T, Niskanen L, Lanke J (2004) Development of diabetes is retarded by ACE inhibition in hypertensive patients–a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens 22:645–652
Nishiyama A, Matsusaka T, Miyata T (2009) Angiotensin II type 1A receptor deficiency and longevity. Nephrol Dial Transplant 24:3280–3281
Nissen SE (2010) Angiotensin-receptor blockers and cancer: urgent regulatory review needed. Lancet Oncol 11:605–606
Parish R, Petersen KF (2005) Mitochondrial dysfunction and type 2 diabetes. Science 5:384–387
Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140–1142
Phillips PA, Rolls BJ, Ledingham JG, Forsling ML, Morton JJ, Crowe MJ, Wollner L (1984) Reduced thirst after water deprivation in healthy elderly men. N Engl J Med 311:753–759
Portero-Otín M, Pamplona R, Boada J, Jové M, Gonzalo H, Buleon M, Linz W, Schäfer S, Tack I, Girolami JP (2008) Inhibition of renin angiotensin system decreases renal protein oxidative damage in diabetic rats. Biochem Biophys Res Commun 368:528–535
Raffaello A, Rizzuto R (2010) Mitochondrial longevity pathways. Biochim Biophys Acta Oct 13. (in press)
Reinehr T (2005) Clinical presentation of type 2 diabetes mellitus in children and adolescents. Int J Obes (Lond) 29:S105–S110
Rink TJ (1984) Aspects of the regulation of cell volume. J Physiol (Paris) 79:388–394
Ritz P (2001) Chronic cellular dehydration in the aged patient. J Gerontol A Biol Sci Med Sci 56:M349–M352
Ritz P, Vol S, Berrut G, Tack I, Arnaud MJ, Tichet J (2008) Influence of gender and body composition on hydration and body water spaces. Clin Nutr 27:740–746
Rogge MM (2009) The role of impaired mitochondrial lipid oxidation in obesity. Biol Res Nurs 10:356–373
Rolls BJ, Phillips PA (1990) Aging and disturbances of thirst and fluid balance. Nutr Rev 48:137–144
Rosen RC, Wing RR, Schneider S, Wadden TA, Foster GD, West DS, Kitabchi AE, Brancati FL, Maschak-Carey BJ, Bahnson JL, Lewis CE, Gendrano Iii IN (2009) Erectile dysfunction in type 2 diabetic men: relationship to exercise fitness and cardiovascular risk factors in the Look AHEAD trial. J Sex Med 6:1414–1422
Rosenthal T, Gavras I (2009) Angiotensin inhibition and malignancies: a review. J Hum Hypertens 23:623–635
Ruilope LM, Segura J (2003) Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clin Ther 25:3044–3064
Saavedra JM, Ando H, Armando I, Baiardi G, Bregonzio C, Juorio A, Macova M (2005) Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists. Regul Pept 128:227–238
Safar ME (2010) Can antihypertensive treatment reverse large-artery stiffening? Curr Hypertens Rep 12:47–51
Safar ME, Temmar M, Kakou A, Lacolley P, Thornton SN (2009) Sodium intake and vascular stiffness in hypertension. Hypertension 54:203–209
Santos EL, de Picoli SK, da Silva ED, Batista EC, Martins PJ, D'Almeida V, Pesquero JB (2009) Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. Biochem Pharmacol 78:951–958
Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A (2008) Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 26:831–843
Savage DB, Petersen KF, Shulman GI (2007) Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 87:507–520
Scheen AJ (2004) Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 64:2537–2565
Scheen AJ (2004) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 30:498–505
Schliess F, Häussinger D (2000) Cell hydration and insulin signalling. Cell Physiol Biochem 10:403–408
Schliess F, Häussinger D (2003) Call volume and insulin signaling. Int Rev Cytol 225:187–228
Schliess F, Richter L, vom Dahl S, Häussinger D (2006) Cell hydration and mTOR-dependent signalling. Acta Physiol (Oxf) 187:223–229
Seeliger E, Wronski T, Ladwig M, Dobrowolski L, Vogel T, Godes M, Persson PB, Flemming B (2009) The renin-angiotensin system and the third mechanism of renal blood flow autoregulation. Am J Physiol Ren Physiol 296:F1334–F1345
Seng WK, Hwang SJ, Han DC, Teong CC, Chan J, Burke TA, Carides GW, Choi YJ (2005) Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective. Nephrology (Carlton) 10:520–524
Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L, Deeb L, Grey M, Anderson B, Holzmeister LA, Clark N, Association AD (2005) Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 28:186–212
Sjögren P, Becker W, Warensjö E, Olsson E, Byberg L, Gustafsson IB, Karlström B, Cederholm T (2010) Mediterranean and carbohydrate-restricted diets and mortality among elderly men: a cohort study in Sweden. Am J Clin Nutr 92:967–974
Stookey JD (2005) High prevalence of plasma hypertonicity among community-dwelling older adults: results from NHANES III. J Am Diet Assoc 105:1231–1239
Stookey JD, Barclay D, Arieff A, Popkin BM (2007) The altered fluid distribution in obesity may reflect plasma hypertonicity. Eur J Clin Nutr 61:190–199
Stookey JD, Constant F, Popkin BM, Gardner CD (2008) Drinking water is associated with weight loss in overweight dieting women independent of diet and activity. Obesity (Silver Spring) 16:2481–2488
Struthers A, Krum H, Williams GH (2008) A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 31:153–158
Stucchi P, Cano V, Ruiz-Gayo M, Fernández-Alfonso MS (2009) Aliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. Br J Pharmacol 158:771–778
Takahashi N, Lopez ML, Cowhig JE Jr, Taylor MA, Hatada T, Riggs E, Lee G, Gomez RA, Kim HS, Smithies O (2005) Ren1c homozygous null mice are hypotensive and polyuric, but heterozygotes are indistinguishable from wild-type. J Am Soc Nephrol 16:125–132
Takai S, Jin D, Ikeda H, Sakonjo H, Miyazaki M (2009) Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats. Hypertens Res 32:853–860
Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, Kano M, Ogihara T, Rakugi H, Morishita R (2009) Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 54:1345–1352
Thornton SN (2009) Angiotensin, the hypovolaemia hormone, aggravates hypertension, obesity, diabetes and cancer. J Intern Med 265:616–617
Thornton SN (2009) Hypovolaemia-induced mild hypoxia produces subchronic metabolic dysfunction. Int J Obes (Lond) 33:605
Thornton SN (2009) Angiotensin, the hormone to be blocked by antithypertensive drugs, and perhaps why they don't work. Curr Vasc Pharmacol 7:549
Thornton SN (2010) Thirst and hydration: physiology and consequences of dysfunction. Physiol Behav 100:15–21
Thornton SN (2010) Angiotensin antagonists could increase urine production and drinking in order to decrease renal problems in diabetes and hypertension. Hypertens Res 33:88
Thornton SN, Even PC, van Dijk G (2009) Hydration increases cell metabolism. Int J Obes (Lond) 33:385
Van Buren PN, Adams-Huet B, Toto RD (2010) Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. J Investig Med Oct 27. (in press)
van Lieburg AF, Knoers NV, Monnens LA (1999) Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 10:1958–1964
Waldegger S, Busch GL, Kaba NK, Zempel G, Ling H, Heidland A, Häussinger D, Lang F (1997) Effect of cellular hydration on protein metabolism. Miner Electrolyte Metab 23:201–205
Weisinger RS, Begg DP, Chen N, Jois M, Mathai ML, Sinclair AJ (2007) The problem of obesity: is there a role for antagonists of the renin-angiotensin system? Asia Pac J Clin Nutr 16:359–367
Weisinger HS, Begg DP, Egan GF, Jayasooriya AP, Lie F, Mathai ML, Sinclair AJ, Wark JD, Weisinger RS (2008) Angiotensin converting enzyme inhibition from birth reduces body weight and body fat in Sprague-Dawley rats. Physiol Behav 93:820–825
Weisinger RS, Begg DP, Jois M (2009) Antagonists of the renin-angiotensin system and the prevention of obesity. Curr Opin Investig Drugs 10:1069–1077
Weisinger RS, Stanley TK, Begg DP, Weisinger HS, Spark KJ, Jois M (2009) Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. Physiol Behav 98:192–197
Zou K, Michikawa M (2008) Angiotensin-converting enzyme as a potential target for treatment of Alzheimer's disease: inhibition or activation? Rev Neurosci 19:203–212
Acknowledgements
The author would like to express his sincere thanks to Professor Ralph Norgren and to Dr Patrick Even for the very valuable discussions during the development of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thornton, S.N. Angiotensin inhibition and longevity: a question of hydration. Pflugers Arch - Eur J Physiol 461, 317–324 (2011). https://doi.org/10.1007/s00424-010-0911-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00424-010-0911-4